Norwalk, Conn., December 1, 2016 – The Multiple Myeloma Research Foundation (MMRF) today announced that 19 research presentations from the MMRF CoMMpass StudySM—the largest and most comprehensive study driving new genomic insights and accelerating precision medicine in multiple myeloma—will be presented at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego from December 3-6. The new analyses are helping to optimize treatment strategies, as well as identify pathways and targets for new drug development.
Findings will also be presented by the Multiple Myeloma Research Consortium (MMRC) that demonstrate the safety and efficacy of four novel treatments.
“Data sharing and collaboration are vital to driving innovation and accelerating new and better treatments for patients,” said Paul Giusti, President and Chief Executive Officer of the MMRF. “We are proud that the MMRF CoMMpass Study is now the largest genomics data set in all of cancer, and grateful to our partners and the patients who made this possible. The exciting data presented at the ASH Annual Meeting validate our collaborative, visionary model to speeding the development of precision medicine approaches that will be critical to improving patient outcomes.”
Among the analyses from the MMRF CoMMpass Study are four presentations helping to define which patients are at a higher risk of early relapse, defined as less than 18 months following first-line therapy. Additionally, these analyses uncovered that some of the identified genetic defects associated with early relapse could be treated with drugs currently being used for other cancers, while others are new targets for the next generation of anti-myeloma drugs.
Another analysis from the MMRF CoMMpass Study identified that patients with a high level of genetic mutations also had high levels of neoantigens (potential natural targets of the immune system), and suggested that those patients had inferior outcomes when treated with the current standard of care. However, there are now novel agents able to stimulate the immune system and these findings offer a promising basis for pursuing tailored immunotherapeutic approaches for multiple myeloma, especially for those patients with a higher mutational burden.
Additionally, new data being presented at ASH from eight trials led by the MMRC have demonstrated initial efficacy and safety of four new therapies, as well as the encouraging activity of novel combination therapies and treatments across various stages of multiple myeloma. The MMRC is the MMRF’s clinical network of centers of excellence, consisting of 22 academic institutions.
“Despite advancements in treatment, an estimated 12,650 Americans die each year from multiple myeloma,” said Dr. Sagar Lonial, Chair Department of Hematology and Medical Oncology and CMO Winship Cancer Institute of Emory University, Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and Global Lead Investigator for the MMRF CoMMpass Study. “The MMRF has made an unprecedented investment to advance the understanding of multiple myeloma at a genomic level and accelerate precision medicine. We reject the idea that progress cannot be made and are committed to ensuring all patients have options available when they need them based on science and data.”
Specific results from the MMRC-led trials include:
- A phase II trial showing that a combination of EMPLICITITM (elotuzumab), REVLIMID® (lenalidomide) and dexamethasone for the treatment of high-risk patients with smoldering myeloma resulted in a 97% clinical benefit rate. (Abstract # 976)
- A phase II study evaluating extended treatment of patients undergoing autologous stem cell transplant with the combination of KYPROLIS® (carfilzomib), REVLIMID® (lenalidomide) and dexamethasone showed improvements in disease progression and survival. (Abstract # 675)
- Five early-phase studies evaluated 4 new compounds, selinexor, isatuximab, marizomib, ventoclax all showing promising efficacy in patients that had previously received many lines of therapy.
About the MMRF CoMMpass Study
The MMRF CoMMpass Study is a longitudinal study of patients with newly diagnosed active multiple myeloma. The goal is to map the genomic profile of each patient to clinical outcomes to develop a more complete understanding of patient responses to treatments. A cornerstone of the MMRF’s Personalized Medicine Initiative, the study is collecting and analyzing tissue samples, clinical data and genetic information from 1,000 newly diagnosed multiple myeloma patients for at least nine years.
The study is designed to show which treatments are used most often as first and subsequent lines of therapy, and to correlate this information with critical therapeutic response criteria including best responses achieved, overall survival, time to disease progression and quality of life measures. Each patient enrolled in the study is required to receive an approved proteasome inhibitor, immunomodulatory drug or both.
The MMRF CoMMpass Study opened in July of 2011 and now includes 1,000 patients from more than 100 sites in the United States, Canada and European Union. Data from the MMRF CoMMpass Study is made available to researchers via the MMRF’s Researcher Gateway (http://research.themmrf.org), an online, open-access portal designed to make key genomic and clinical data available for additional study. The MMRF CoMMpass Study is being supported through a public-private partnership of patient donors and industry partners, including Takeda Oncology, Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Inc. and Janssen Diagnostics. Additional collaborating research partners include the Translational Genomics Research Institute, Van Andel Research Institute and GNS Healthcare.
Please visit www.themmrf.org/research-partners/the-commpass-study to learn more about the study.
About Multiple Myeloma
Multiple myeloma (MM) is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 30,330 adults (17,900 men and 12,430 women) in the United States will be diagnosed with MM in 2016 and an estimated 12,650 people are predicted to die from the disease. The five-year survival rate for MM is approximately 47%, versus 31% in 1999.
About the Multiple Myeloma Research Foundation (MMRF)
The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $330 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.
About the Multiple Myeloma Research Consortium
The Multiple Myeloma Research Consortium (MMRC) is a 509 (a) 3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 22 member institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center Home, Beth Israel Deaconess, Brigham and Women’s Hospital, Mayo Clinic (Jacksonville, Rochester and Scottsdale), Baylor Charles A. Sammons Cancer Center at Dallas, Barbara Ann Karmanos Cancer Institute, City of Hope, Emory University’s Winship Cancer Institute, Levine Cancer Institute, The John Theurer Cancer Center at Hackensack University Medical Center, Mount Sinai School of Medicine, Ohio State University, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California, San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists and Washington University in St. Louis.
The MMRC is the only consortium in multiple myeloma to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit www.themmrc.org.
Anne Quinn Young
Senior Vice President, Marketing & Communications
Multiple Myeloma Research Foundation